BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
金曜日, 9 25

Bio-Techne Corp

TECHNASDAQ
Trade with Public
Trade with Public
$72.57
0.050.07%
近くで: Sep 24, 5:00 PM EST
$72.57
N/A
時間外: 4:00 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成配当比較オプション株式レポート

Bio-Techne Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bio-Techne (TECH).

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

3Buy
9Hold
Consensus RatingBuy# Analysts12Avg. Consensus PT$72Upside to Avg. PT-0.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →
DateFirmAnalystActionRating ChangePrice Target
Aug 13, 2026Wells FargoEvan StamplerDowngradeOverweight→Equal-Weight$62→$73
Jul 9, 2026RBC CapitalDan LeonardDowngradeOutperform→Sector Perform$62→$73
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73

Wells Fargo analyst Brandon Couillard downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $62 to $73.
Benzinga Newsdesk

PRO
RBC Capital Downgrades Bio-Techne to Sector Perform, Raises Price Target to $73

RBC Capital analyst Dan Leonard downgrades Bio-Techne (NASDAQ:TECH) from Outperform to Sector Perform and raises the price target from $62 to $73.
Benzinga Newsdesk

PRO
TD Cowen Downgrades Bio-Techne to Hold, Raises Price Target to $73

TD Cowen analyst Kyle Boucher downgrades Bio-Techne (NASDAQ:TECH) from Buy to Hold and raises the price target from $65 to $73.
Benzinga Newsdesk

PRO
Benchmark Downgrades Bio-Techne to Hold

Benchmark analyst Robert Wasserman downgrades Bio-Techne (NASDAQ:TECH) from Buy to Hold.
Benzinga Newsdesk

PRO
Citigroup Downgrades Bio-Techne to Neutral, Raises Price Target to $73

Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and raises the price target from $70 to $73.
Benzinga Newsdesk

PRO
Stephens & Co. Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73

Stephens & Co. analyst Steven Etoch downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $68 to $73.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved